75 related articles for article (PubMed ID: 28119489)
1. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Yan C; Yang J; Saleh N; Chen SC; Ayers GD; Abramson VG; Mayer IA; Richmond A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069042
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
Scheller T; Hellerbrand C; Moser C; Schmidt K; Kroemer A; Brunner SM; Schlitt HJ; Geissler EK; Lang SA
Br J Cancer; 2015 Mar; 112(5):841-50. PubMed ID: 25688743
[TBL] [Abstract][Full Text] [Related]
6. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Meister KS; Godse NR; Khan NI; Hedberg ML; Kemp C; Kulkarni S; Alvarado D; LaVallee T; Kim S; Grandis JR; Duvvuri U
Sci Rep; 2019 Jun; 9(1):9130. PubMed ID: 31235758
[TBL] [Abstract][Full Text] [Related]
7. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Bcl-2-Associated Athanogene-3 Can Enhance the Efficacy of BGJ398 via Suppressing Migration and Inducing Apoptosis in Gastric Cancer.
Li K; Deng X; Feng G; Chen Y
Dig Dis Sci; 2021 Sep; 66(9):3036-3044. PubMed ID: 33089486
[TBL] [Abstract][Full Text] [Related]
9. FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma.
Zhen Y; Liu K; Shi L; Shah S; Xu Q; Ellis H; Balasooriya ER; Kreuzer J; Morris R; Baldwin AS; Juric D; Haas W; Bardeesy N
Nat Commun; 2024 May; 15(1):3805. PubMed ID: 38714664
[TBL] [Abstract][Full Text] [Related]
10. Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Workman P; Clarke PA; Raynaud FI; van Montfort RL
Cancer Res; 2010 Mar; 70(6):2146-57. PubMed ID: 20179189
[TBL] [Abstract][Full Text] [Related]
11. Analyses of the combination of 6-MP and dasatinib in cell culture.
Kaur G; Behrsing H; Parchment RE; Millin MD; Teicher BA
Int J Oncol; 2013 Jul; 43(1):13-22. PubMed ID: 23652925
[TBL] [Abstract][Full Text] [Related]
12. Stage 4 pancreatic adenocarcinoma harbouring an
Poon D; Tan MH; Khor D
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34511423
[TBL] [Abstract][Full Text] [Related]
13. Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.
Heft Neal ME; Michmerhuizen NL; Kovatch KJ; Owen JHJ; Zhai J; Jiang H; McKean EL; Prince MEP; Brenner JC
J Neurol Surg B Skull Base; 2022 Feb; 83(1):87-98. PubMed ID: 35155075
[No Abstract] [Full Text] [Related]
14. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
15. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Yu Y; Hall T; Eathiraj S; Wick MJ; Schwartz B; Abbadessa G
Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
[TBL] [Abstract][Full Text] [Related]
17. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS; Jovcheva E; Mevellec L; Vialard J; De Lange D; Verhulst T; Paulussen C; Van De Ven K; King P; Freyne E; Rees DC; Squires M; Saxty G; Page M; Murray CW; Gilissen R; Ward G; Thompson NT; Newell DR; Cheng N; Xie L; Yang J; Platero SJ; Karkera JD; Moy C; Angibaud P; Laquerre S; Lorenzi MV
Mol Cancer Ther; 2017 Jun; 16(6):1010-1020. PubMed ID: 28341788
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
20. Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickström M; Kostopoulou ON; Dalianis T
Int J Oncol; 2021 Feb; 58(2):211-225. PubMed ID: 33491755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]